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ABSTRACT
Phospholamban (PLB) is an integral membrane protein that plays an
important role in regulation of cardiac calcium handling and contractility. PLB
exists as a homopentamer in the membrane, which upon deoligomerization into
active monomers reversibly inhibits sarco/endoplasmic reticulum calcium
ATPase (SERCA). Mutations in PLB that change the PLB monomer-pentamer
equilibrium result in dysregulation of SERCA. To determine the structural and
regulatory role of the C-terminal residues of PLB in the membranes of living cells,
we fused fluorescent protein tags to PLB and SERCA. We then studied the effect
of

C-terminal

alanine

substitutions

and

truncation

mutations

on

PLB

oligomerization and SERCA regulation by fluorescence resonance energy
transfer (FRET) measurements in live cells. In addition, we also studied the
structural and functional consequences of two naturally-occurring missense
mutations of PLB that cause heart failure including L39stop (L39X) and Arg9Cys
(R9C). Alanine substitution of PLB C-terminal residues significantly altered FRET
from PLB to PLB and SERCA to PLB, suggesting a change in quaternary
conformation of PLB pentamer and SERCA-PLB regulatory complex. We also
quantified a decrease in PLB oligomerization affinity, and an increase in SERCAPLB binding affinity for alanine mutants. Notably, truncation of only a few Cterminal residues resulted in significant loss of PLB membrane anchoring and

xii

mislocalization to the cytoplasm and nucleus. C-terminal truncations including
L39X resulted in progressive loss of PLB-PLB FRET, due to a decrease in the
apparent affinity of PLB oligomerization. In addition, we quantified a decrease in
the binding affinity of truncated PLB including L39X for SERCA, suggesting a
change in quaternary conformation of the SERCA-PLB regulatory complex.
Furthermore, FRET measurements revealed that R9C-PLB exhibited an
increased propensity for oligomerization, and this was further increased by
oxidative stress. The R9C also decreased PLB binding to SERCA, and altered
the structure of the PLB-SERCA regulatory complex. In addition, we observed
that acute expression of R9C-PLB exerts a positively inotropic and lusitropic
effect in cardiomyocytes, in contrast to studies of chronic R9C-PLB expression in
transgenic mice. Importantly, R9C-PLB exhibited blunted sensitivity to frequency
potentiation and β-adrenergic stimulation, two major physiological mechanisms
for the regulation of cardiac performance. We conclude that PLB C-terminal
residues are critical for localization, oligomerization, and regulatory function. In
particular, the PLB C-terminus is an important determinant of the quaternary
structure of the SERCA-PLB regulatory complex. Furthermore, the heart failure
mutants of PLB including L39X and R9C decrease SERCA inhibition by altering
the structure and function of the SERCA-PLB regulatory complex.

xiii

CHAPTER I
INTRODUCTION
Cardiac Calcium Cycling and Contractile Function
The cardiac cycle constitutes the phases of contraction (systole) and
relaxation (diastole) of the heart that together constitute the heart beat (Fukuta
and Little 2008). During systole, the action potential causes membrane
depolarization and induces a calcium (Ca2+) influx through the L-type Ca2+
channels (Bers 2002). This influx triggers the Ca2+-induced Ca2+ release from the
sarcoplasmic reticulum (SR) via ryanodine receptors (RyR) (Bers 2002). The
schematic representation of the key players involved in regulation of cardiac Ca2+
cycling and contractile function is shown in Fig. 1 (Bers 2002, 2008). The Ca2+
release from the SR via RyRs gives rise to the Ca2+ transient and the resultant
rise in intracellular Ca2+ activates the myofilaments to produce cardiac
contraction (inotropy). This is indicated by the rising phase of the Ca2+ transient,
followed by the shortening of the sarcomere length during contraction of the
myofilaments. During diastole, the RyRs close and the released Ca2+ is pumped
back into the SR by sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) that
results in cardiac relaxation (lusitropy). The resultant decrease in intracellular
Ca2+ is indicated by the decay phase of the Ca2+ transient, which is followed by
sarcomere relengthening during relaxation of the myofilaments. SERCA is under
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the inhibitory control of a small inhibitory phosphoprotein, phospholamban (PLB)
that decreases the Ca2+ affinity for SERCA (MacLennan and Kranias 2003). This
process of cardiac Ca2+ cycling is highly regulated and is repeated for each beat
of the heart to maintain normal Ca2+ homeostasis and cardiac function. Thus,
SERCA-PLB regulatory complex plays a central role in regulation of cardiac Ca2+
cycling and contractile function (Kranias and Hajjar 2012). Dysregulation of
SERCA-PLB complex results in pathological consequences, and targeting
abnormal Ca2+ kinetics has emerged as a promising therapeutic target for
treatment of human heart failure (Kranias and Hajjar 2012).
SERCA
SERCA is an ion-motive P-type ATPase that establishes intracellular Ca2+
stores needed for cell signaling (Lipskaia, Hulot, and Lompré 2009) and normal
cardiac myocyte function. SERCA is a 110 kDa integral SR membrane protein,
which utilizes ATP hydrolysis to transport Ca2+ into the SR (MacLennan and
Kranias 2003). In human and rabbit ventricular cardiomyocytes, 70% of the
cytoplasmic Ca2+ is removed by SERCA, 28% by the Na+/Ca2+ exchanger, 1% by
the sarcolemmal Ca2+-ATPase and 1% by the mitochondrial Ca2+ uniporter (Bers
2002). During the enzymatic cycle, SERCA cycles between two primary
conformations: the Ca2+-bound state (E1) and the Ca2+-unbound state (E2)
(Toyoshima and Inesi 2004). The first high resolution (2.6 Å) crystal structure of
SERCA with two Ca2+ ions bound in the E1 state was determined by Toyoshima
and coworkers (Toyoshima et al. 2000). The same group later reported the
crystal structure of SERCA in a Ca2+-free E2 state at 3.1 Å resolution (Toyoshima
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and Nomura 2002). The structure of SERCA constitutes four functional domains:
nucleotide-binding (N), phosphorylation (P), actuator (A) and transmembrane
(TM) as shown in Fig. 2 (Toyoshima and Inesi 2004). The N-domain contains the
ATP-binding site and is responsible for placement of ATP to facilitate
autophosphorylation, the P-domain forms the catalytic core of the enzyme and
contains the autophosphorylated residue (Asp351), the A domain is involved in
the transmission of major conformational dynamics following Ca2+ binding and
translocation, and the TM domain constitutes 10 helices (M1-M10) and two Ca2+
binding sites (Toyoshima and Inesi 2004).
In humans, three SERCA genes, SERCA 1, 2 and 3 encode up to 10
isoforms (SERCA1a-b, SERCA2a-c, SERCA3a-f) by developmental or tissuespecific alternative splicing (Periasamy and Kalyanasundaram 2007). SERCA1 is
mainly expressed in fast-twitch skeletal muscle and has two isoforms, SERCA1a
(adult) and SERCA1b (neonatal) (Brandl et al. 1987, Brandl et al. 1986, Peters et
al. 1997). SERCA2 has three isoforms, SERCA2a (cardiac and slow-twitch
skeletal muscle tissue), SERCA2b (ubiquitously expressed in all tissues) and
SERCA2c (cardiac muscle) (Dally et al. 2006). SERCA3 has six isoforms,
SERCA3a-f, which are expressed in multiple tissues and cell types (Dally et al.
2009, Wuytack et al. 1995). The domain structure of SERCA isoforms is highly
conserved, but they have varying affinities for Ca2+ and transport velocities
(Periasamy and Kalyanasundaram 2007).
The cardiac SERCA isoform (SERCA2a) plays a critical role in regulating
cardiac contraction and relaxation (Frank et al. 2003). During the cardiac cycle,
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into the SR at the expense of ATP hydrolysis by SERCA is

the fundamental mechanism for initiation of cardiac muscle relaxation during
diastole (Kranias and Hajjar 2012, MacLennan and Kranias 2003, Periasamy and
Huke 2001). Moreover, the rate of SERCA Ca2+ uptake is one of the main
determinants of the size of the Ca2+ store, so SERCA is also critical for regulating
the strength of cardiac contraction during systole (Kranias and Hajjar 2012,
MacLennan and Kranias 2003, Periasamy and Huke 2001). SERCA facilitates
the storage and distribution of Ca2+ ions in the SR by maintaining a 1000-fold
Ca2+ gradient across the SR membrane (Frank et al. 2003). By actively
transporting Ca2+ ions into the SR, SERCA regulates cytosolic Ca2+
concentration, SR Ca2+ load, and cardiac inotropy and lusitropy. Alteration of the
activity and expression of SERCA contributes to the decreased SR Ca2+ content,
resulting in cardiac dysfunction during heart failure (Periasamy, Bhupathy, and
Babu 2008).
Phospholamban
SERCA2a activity is closely governed by an inhibitory interaction with its
regulatory

partner

phospholamban

(PLB),

a

52

residue

single

span

transmembrane peptide (Kranias and Hajjar 2012, MacLennan and Kranias
2003, Simmerman and Jones 1998). PLB is predominantly expressed in cardiac
muscle (Simmerman and Jones 1998) and in small amounts in smooth muscle
(Raeymaekers and Jones 1986), slow-twitch skeletal muscle (Movsesian et al.
1992) and endothelial cells (Sutliff et al. 1999). PLB is a homopentameric,
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integral SR membrane protein, which upon deoligomerization into active
monomers reversibly inhibits SERCA (Simmerman and Jones 1998, Karim et al.
1998, Robia et al. 2007), thereby directly regulating cardiac Ca2+ kinetics and
contractility (Park and Oh 2013, Kranias and Hajjar 2012, MacLennan and
Kranias 2003). The primary sequence and structural domains of PLB monomer
determined by solid-state NMR spectroscopy have been highlighted in Fig. 3.
PLB has a 'helix-loop-helix' tertiary structure consisting of an N-terminal cytosolic
domain IA (residues 1-16), flexible linker (residues 17-22), domain IB (residues
23-30), and the C-terminal transmembrane (TM) domain II (residues 31-52)
(Verardi et al. 2011, Zamoon et al. 2003).
The C-terminal TM domain is hydrophobic, highly conserved among
species (Simmerman and Jones 1998), and is important for PLB oligomerization
(Simmerman et al. 1996, Fujii et al. 1989), and SERCA regulation (Kimura et al.
1996). The key residues in the TM domain of PLB that are critical for pentamer
formation and stability have been identified by the alanine- and phenylalaninescanning mutagenesis studies (Simmerman et al. 1996), and subsequently
supported by the NMR studies (Verardi et al. 2011). It has been shown that the
PLB homopentamer is formed and stabilized by a leucine-isoleucine zipper by
the close packing of Leu37, Ile40, Leu44, Ile47, and Leu51 (Simmerman et al.
1996). In addition, mutagenesis studies have shown that three TM cysteines
(Cys36, Cys41 and Cys46) contribute to PLB pentamer stability on account of
their steric properties, but not intermolecular disulfide bonding (Karim et al.
2001).
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The N-terminal cytoplasmic domain is hydrophilic, and undergoes
conformational changes in the PLB oligomer and SERCA-PLB regulatory
complex as a result of mutations, or phosphorylation (Gustavsson et al. 2013,
Glaves et al. 2011, Hou, Kelly, and Robia 2008). The cytoplasmic domain of PLB
can be phosphorylated at Ser16 by cAMP-dependent protein kinase A (PKA) and
at Thr17 by Ca2+/calmodulin-dependent protein kinase II (CaMKII) (MacLennan
and Kranias 2003, Hagemann and Xiao 2002). Several hereditary mutations in
PLB have been shown to cause dilated cardiomyopathy and heart failure
(Medeiros et al. 2011). The mutations in the PLB cytoplasmic domain that result
in diseases include Arg9-to-Cys (R9C) (Schmitt et al. 2003), deletion of Arg14
(R14del) (Haghighi et al. 2006, DeWitt et al. 2006, Posch et al. 2009, van
Rijsingen et al. 2014), Arg9-to-Leu (R9L) and Arg9-to-His (R9H) (Medeiros et al.
2011). The truncation at Leu39 (L39X) is the only hereditary mutation in the TM
domain of PLB that causes heart failure (Haghighi et al. 2003). The heart failure
mutants of PLB that are the focus of this study are discussed in greater detail in
the section “Mutations in human PLB gene linked to heart failure”.
PLB Inhibition of SERCA
In the SR membrane, PLB exists in a dynamic equilibrium between the
homopentamer and the monomer (Fig. 4). Monomeric PLB is the active inhibitory
species of SERCA, and the pentamer acts as the storage of inactive form of PLB
(MacLennan and Kranias 2003, Kimura et al. 1997). KD1 and KD2 represent the
dissociation constants for PLB pentamer and PLB-SERCA regulatory complex,
respectively (Robia et al. 2007, MacLennan and Kranias 2003). Importantly, PLB

10

Figure
F
4. Dynamic equilibrium
m betwee
en PLB pentamer a
and mono
omer
re
egulates SERCA.
S
PL
LB homope
entamer de
eoligomerizzes into acctive monom
mers
th
hat bind an
nd inhibit SERCA. Disrupting
D
P
PLB monomer-pentam
mer equilib
brium
le
eads to SERCA dys
sregulation. (KD1, KD 2: Dissociiation consstants for PLB
pentamer an
nd PLB-SE
ERCA regulatory comp
plex, respectively). Structural mo
odels
of PLB and SERCA
S
we
ere generate
ed using PyyMOL (PDB
B: 2KYV, 1IWO).

11
monomer-pentamer equilibrium plays an important role in the inhibition of
SERCA, and is required for optimal regulation of contractile function of the heart
(MacLennan and Kranias 2003). Any changes in PLB monomer-pentamer
equilibrium via mutations in PLB or phosphorylation of PLB result in
dysregulation of SERCA (MacLennan and Kranias 2003).
During the cardiac cycle, the unphosphorylated PLB monomer interacts
with SERCA at resting Ca2+ concentration, reducing SERCA’s apparent affinity
for Ca2+ and decreasing its activity (MacLennan and Kranias 2003, Kranias and
Hajjar 2012). Several models are proposed in the literature for the mechanism for
relief of inhibition, which is still an active area of investigation. The PLB inhibition
of SERCA is partially relieved upon β-adrenergic stimulation, when PKA
phosphorylates PLB at Ser-16 (MacLennan and Kranias 2003, Hagemann and
Xiao 2002), increasing SERCA activity to meet increased physiological demand.
A complementary mechanism for relief of inhibition is PLB phosphorylation at
Thr-17 by CaMKII (Hagemann and Xiao 2002). This pathway is activated by the
elevation of cytosolic Ca2+ that accompanies increased pacing frequency during
exercise. A previous study in our lab has shown that phosphomimetic mutations
at both PKA and CaMKII sites result in increased oligomerization of PLB to form
pentamers as well as altered the structure of SERCA-PLB regulatory complex
(Hou, Kelly, and Robia 2008). In addition, direct phosphorylation of SERCA at
Ser-38 by CaMKII has also been reported to increase SERCA activity (Toyofuku,
Curotto Kurzydlowski, et al. 1994, Narayanan and Xu 1997). Thus, SERCA
activity and PLB regulation of that activity by phosphorylation or mutations may
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allow the heart to responsively compensate for rest, stress, or diseased
conditions.
Notably, it has been reported that PLB inhibition of SERCA is also relieved
by elevated cytosolic Ca2+ concentration (Asahi et al. 2000). However, several
mechanisms for this functional effect have been proposed. According to the
‘dissociation model’, monomeric PLB binds selectively to the Ca2+-free “E2”
conformation of SERCA during cardiac relaxation when cytoplasmic Ca2+
concentration is low (Akin, Chen, and Jones 2010, Chen, Akin, and Jones 2010,
Chen et al. 2006). The relief of SERCA inhibition results in unbinding of PLB from
the Ca2+-bound E1 conformation during cardiac contraction when cytoplasmic
Ca2+ concentration is high (Akin, Chen, and Jones 2010, Chen, Akin, and Jones
2010, Chen et al. 2006). According to the ‘subunit model’, PLB remains bound to
SERCA throughout the catalytic cycle and acts as a subunit of the pump (Mueller
et al. 2004). Alternatively, our lab has previously proposed a model according to
which the relief of functional inhibition does not require dissociation of the
SERCA-PLB regulatory complex, and PLB can bind SERCA at high Ca2+
concentration, although with a lower binding affinity (Bidwell et al. 2011). This
study suggested multiple modes of PLB binding or presence of alternative
binding sites on SERCA. The present study supports that mutations in PLB
cause translocation of PLB TM domain from canonical binding site to an
alternative binding site on SERCA, resulting in alteration of the structure and
function of SERCA-PLB regulatory complex.
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Mutagenesis studies have reported that the residues Leu31, Asn34,
Phe35, Ile38, and Leu42 in the TM domain of PLB are essential for inhibition of
SERCA (Kimura et al. 1997). In addition, cross-linking studies and modeling of
PLB-SERCA regulatory interaction has shown that the TM domain of PLB is
accommodated in a groove formed by helices M2, M4, M6 and M9 of SERCA
(Toyoshima et al. 2003). Another study has shown that the sequence Lys–Asp–
Asp–Lys–Pro–Val-402 in the N-domain of SERCA is important for PLB inhibitory
interaction (Toyofuku, Kurzydlowski, et al. 1994). Cryo-electron microscopy
revealed a low-resolution structure of a co-crystal between SERCA and PLB, but
it did not give any information about the binding site (Young, Jones, and Stokes
2001). A recent study reported the crystal structure of SERCA in complex with
PLB at 2.8 Å resolution (Akin et al. 2013). This study revealed the interaction of
SERCA with transmembrane domain of PLB, but it did not give information about
the binding of cytoplasmic domain of PLB with SERCA. It is important to note that
the structure and function of the SERCA-PLB regulatory complex may be altered
by mutations in PLB or SERCA. Although these structural studies provide
mechanistic information about the interaction between PLB and SERCA, they
may not reveal the physiological interaction of the regulatory complex. In this
study, FRET analysis provided insight into the effect of specific mutations on the
alteration of quaternary conformation and function of PLB-SERCA regulatory
complex in real time. The structural studies of SERCA-PLB regulatory complex
interaction is still an active area of research.
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Mutations in Human PLB Gene Linked to Heart Failure
Disordered Ca2+ transport or regulation may cause and result from cardiac
diseases such as heart failure (Marks 2003, Asp et al. 2013, Luo and Anderson
2013). Heart failure is a leading cause of mortality, affecting an estimated 26
million people worldwide, and up to 6 million people in the US (Lopez-Sendon
2011). Dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM)
are the leading causes of heart failure (Towbin and Bowles 2002, Kimura 2008).
Both DCM and HCM can be caused by mutations in genes encoding cardiac
Ca2+ handling proteins including PLB (Kimura 2008, Medeiros et al. 2011,
Haghighi et al. 2003, Chiu et al. 2007, Landstrom et al. 2011, Schmitt et al. 2003,
Haghighi et al. 2006, DeWitt et al. 2006, Posch et al. 2009, van Rijsingen et al.
2014). In particular, mutations (Schmitt et al. 2003, Haghighi et al. 2003,
Medeiros et al. 2011, Landstrom et al. 2011) or deletions (Haghighi et al. 2006,
DeWitt et al. 2006, Posch et al. 2009, van Rijsingen et al. 2014) of PLB give rise
to human disease, underscoring the importance of this peptide and providing
some insight into the molecular mechanisms of SERCA regulation by PLB.
Of particular interest is the human heart failure mutant R9C-PLB, which
was identified in 2003 to be the first DCM causing human mutation of PLB
(Schmitt et al. 2003). This mutation is caused by heterozygous substitution of
Arg9 for Cys in the cytoplasmic domain of PLB. DCM is a leading cause of
cardiovascular morbidity and mortality worldwide (Jefferies and Towbin 2010,
Dellefave and McNally 2010, Parvari and Levitas 2012), so there is great interest
in understanding how a discrete point mutation in PLB could induce pathological

15
dysfunction. The patients with R9C-PLB mutation had early symptom onset at
the age of 20 to 30 years, and required cardiac transplantation depending on
severity of the disease (Schmitt et al. 2003). The affected individuals suffered
from progressive heart failure 5 to 10 years later and their average age at death
was 25.1 ± 12.7 years (Schmitt et al. 2003). The proposed mechanisms for R9C
pathology

have

been

discussed

in

detail

in

Sections

‘Disordered

structure/function mechanisms of R9C-PLB’ and ‘R9C Acts as a Phosphomimetic
Mutation of PLB’ of Chapter V.
Another naturally-occurring missense mutation in PLB that leads to heart
failure is caused by substitution of a stop codon for Leu39 (L39X) (Haghighi et al.
2003). This mutation results in truncation of the C-terminus of PLB midway
through its TM domain (Haghighi et al. 2003). This mutation has been reported to
cause dysregulation of SR Ca2+ cycling, DCM, HCM, heart failure and premature
death in humans (Haghighi et al. 2003, Chiu et al. 2007, Landstrom et al. 2011).
The patients heterozygous for this mutation exhibited hypertrophy without
diminished contractile function (Haghighi et al. 2003). However, homozygous
patients developed heart failure and early mortality, requiring cardiac
transplantation between ages 16 and 27 (Haghighi et al. 2003). In humans, this
mutant has been reported as a highly unstable, rapidly degraded and inactive
form of PLB. On account of loss of myocardial PLB protein content and a
resultant loss of PLB inhibitory function, the homozygous L39X individuals were
described as PLB-null (Haghighi et al. 2003). In contrast, PLB ablation in mouse
models results in chronically enhanced basal cardiac contractile function without
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development of heart failure, even in advanced age (Luo et al. 1994). The critical
differences between cardiac phenotypes on account of PLB ablation in mouse
and humans emphasizes the need to better understand the pathophysiological
differences between the two species. While all other naturally-occurring human
PLB mutations have been identified in the cytoplasmic domain, L39X is unique to
the TM domain of PLB (Haghighi et al. 2003).
This shows that PLB is important for cardiac function and hereditary
mutations in PLB are a cause of heart failure in humans. In this study, we
investigated the role of the R9C-PLB mutation in determining the structure of
SERCA-PLB

regulatory

complex

as

well

as

the

acute

physiological

consequences of this mutation on SR Ca2+ handling and contractile function.
Additionally, in order to understand the role of the TM domain in membrane
anchoring, localization, PLB oligomerization, and SERCA regulation, we
investigated the structural and functional consequences of subjecting the PLB
TM domain to alanine substitution mutations and truncation mutations including
L39X (Abrol et al. 2014). In addition to R9C (Schmitt et al. 2003) and L39X
(Haghighi et al. 2003), other genetic mutations in human PLB linked to heart
failure are R14del (Haghighi et al. 2006, DeWitt et al. 2006, Posch et al. 2009,
van Rijsingen et al. 2014), R9L and R9H (Medeiros et al. 2011). The
identification of additional human PLB mutants will further explain the functional
role of PLB in cardiac physiology and its effects on genetic predisposition to
cardiac diseases.

CHAPTER II

MATERIALS AND METHODS
Molecular Biology
mCerulean (Cer), cyan fluorescent protein (CFP), or enhanced yellow
fluorescent protein (YFP) were each fused to the N-terminus of canine PLB or
canine SERCA2a as described previously (Abrol et al. 2014, Bidwell et al. 2011,
Hou and Robia 2010, Kelly et al. 2008, Robia et al. 2007). Fig. 5A represents the
primary amino acid sequence of WT-PLB with the domains highlighted. The
R9C-PLB mutant was generated by mutating the cytoplasmic Arg 9 residue to
Cys (Fig. 5B). The SSS-PLB mutant was constructed by mutating the
transmembrane Cys residues 36, 41, and 46 to Ser (Fig. 5B). As shown in Fig.
5C, a series of truncation mutants of PLB were constructed by introducing stop
codons at residues 52, 51, 50, 49, 48, 39, 38, or 33 (Abrol et al. 2014). In
addition, alanine (Ala) substitution mutants were generated by replacing the
residues 52, 51, 50, or 49 by Ala (Fig. 5C) (Abrol et al. 2014). All the PLB
mutants used in this study were generated using the QuikChange IIXL sitedirected mutagenesis kit (Stratagene, La Jolla, CA) and custom oligonucleotide
primers (Eurofins MWG Operon). The nucleotide sequences were verified by
DNA sequencing (ACGT, Inc.). Adenoviral vectors of canine CFP-PLB or YFPPLB were produced using AdEasy Adenoviral Vector System (Stratagene, CA).
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Cell Culture
Left ventricular cardiomyocytes were enzymatically isolated from adult New
Zealand White rabbits (Domeier, Blatter, and Zima 2009). All animal protocols
including cardiomyocyte isolation was approved by the Loyola University
Institutional Animal Care and Use Committee. The cardiomyocytes were washed
with fresh PC-1 medium (Lonza, Basel, Switzerland) and plated onto laminincoated glass coverslips that fit into 35 mm culture dishes. Cardiomyocytes were
incubated at 37°C for 1 hour and CFP-PLB and/or YFP-PLB adenoviruses were
added at a multiplicity of infection of 1000 as previously (Pallikkuth et al. 2013).
Cardiomyocytes were then paced for 48 hours in culture using a C-Pace EP
Pacer (IonOptix, Milton, MA) set to 10 volts with a frequency of 0.1 Hz, with 5 ms
pulse duration (Bidwell et al. 2011, Pallikkuth et al. 2013).
AAV-293 cells were cultured in 60-mm tissue culture dishes in complete
DMEM growth medium with 10% fetal bovine serum, 1% L-glutamine and
incubated at 37°C under 5% CO2. Transient transfection of cultured AAV-293
cells was performed by the calcium phosphate precipitation method using the
MBS mammalian transfection kit (Stratagene, La Jolla, CA). Cells were cotransfected with plasmids encoding Cer-PLB and YFP-PLB or Cer-SERCA and
YFP-PLB with a molar ratio of 1:5 or 1:20 respectively (Abrol et al. 2014, Bidwell
et al. 2011). Following transfection, the cells were subjected to mild
trypsinization, plated on poly-D-lysine-coated glass bottom dishes, and allowed
to adhere for 2 hours before imaging, as described previously (Abrol et al. 2014,
Bidwell et al. 2011).
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Fluorescence Resonance Energy Transfer (FRET) Quantification
PLB oligomerization and interaction with SERCA was quantified in live
cells using wide-field fluorescence microscopy as described previously (Abrol et
al. 2014, Bidwell et al. 2011). MetaMorph software was used for acquisition of a
montage of 48 images using a motorized stage (Prior, Rockland, MA). Focus
was automatically maintained by an optical feedback system (Perfect Focus
System, Nikon), and image acquisition was done using 40X objective with a
numerical aperture of 0.75. The exposure time was 150 ms for each channel:
Cer, YFP, and FRET (Cer excitation/YFP emission). Multi Wavelength Cell
Scoring application module in MetaMorph was used for automated quantification
of fluorescence intensity. The cells were selected by the software based on the
criteria including minimum fluorescent area of 50 µm2, diameter between 40 µm
and 100 µm, and an average intensity of 100 counts above background. The
average intensities of each channel were then transferred to a spreadsheet for
quantifying FRET efficiency. FRET quantification was done using acceptor
sensitization (E-FRET) (Zal and Gascoigne 2004), as described previously
(Abrol et al. 2014, Bidwell et al. 2011). After background subtraction, FRET
efficiency was calculated according to the following formula: E = [IDA – a(IAA) –
d(IDD)] / [IDA – a(IAA) + (G – d ) (IDD)]; where IDD is the intensity of fluorescence
emission from the donor channel (472/30 nm) with excitation of 427/10 nm; IAA is
the intensity of fluorescence emission from the acceptor channel (542/27 nm)
with excitation of 504/12 nm; and IDA is the intensity of fluorescence emission
detected in the FRET channel (542/27 nm) with excitation of 427/10 nm. The
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constants a and d are cross-talk coefficients determined from acceptor-only or
donor-only control samples, respectively, a = IDA / IAA , and d = IDA / IDD. G
represents the ratio of the sensitized emission to the corresponding amount of
donor recovery. For the R9C-PLB FRET experiments, we used values of 0.082,
0.82 and 3.2 for a, d and G ratio respectively, as described previously (Bidwell et
al. 2011). For the truncation mutations and alanine substitution FRET
experiments, we obtained values of 0.083, 0.69 and 4.3 for a, d and G ratio
respectively (Abrol et al. 2014).
For time-course experiments, the cells were imaged at 30 s time intervals
for Cer, YFP, and FRET channels. After 5 min of image acquisition, 100 µM
hydrogen peroxide (H2O2) was applied and the cells were imaged every 30 s for
an additional 20 minutes. The FRET efficiency for individual cells at each time
point was quantified using MetaMorph and the data from 3 independent
experiments were averaged. The FRET ratio was calculated by dividing the
intensity of FRET channel by the intensity of Cer channel. The calculated FRET
ratios for all the cells at each time point were averaged after normalizing to the
first time point. FRET images were acquired by dividing the image of FRET
channel by Cer fluorescence using MetaMorph.
‘In-Cell’ Binding Assay
An ‘in-cell’ binding assay was performed to estimate the parameters
related to structure and binding affinity (Abrol et al. 2014, Bidwell et al. 2011, Ha
et al. 2011, Hou and Robia 2010, Hou, Kelly, and Robia 2008, Kelly et al. 2008).
Briefly, the FRET efficiency of individual cells coexpressing Cer-PLB/YFP-PLB or
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Cer-SERCA/YFP-PLB was plotted against relative protein concentration, which
was quantified from the observed YFP fluorescence intensities. Fig. 6A shows
AAV-293 cells expressing Cer-PLB and YFP-PLB. An example of PLB-PLB
binding curve is shown in Fig. 6B. The concentration dependence of FRET was
fit to a hyperbolic curve of the form y = (FRETmax)x / (KD + x), with all parameters
independently fit, where y is the observed FRET efficiency, and x is the protein
concentration in the cell in arbitrary units (AU). FRETmax is the intrinsic FRET of
the protein complex and a measure of average distances between the binding
partners, providing structural information. KD is the protein concentration that
yields half FRETmax, and represents the dissociation constant of the protein
complex, providing an estimate of the apparent binding affinity.
KD1 is the apparent dissociation constant of the PLB oligomer and KD2 is the
apparent dissociation constant of the SERCA-PLB regulatory complex. The data
are pooled from 3 to 4 independent experiments for each sample. Each binding
curve was developed by using an average of approximately 2000 cells. The
effect of mutations on PLB oligomerization affinity or SERCA-PLB binding affinity
can be directly measured in real-time by estimating the changes in KD1 or KD2
respectively from the binding curve (Abrol et al. 2014, Bidwell et al. 2011, Ha et
al. 2011, Hou and Robia 2010, Hou, Kelly, and Robia 2008, Kelly et al. 2008). As
shown in Fig. 6B, the red and blue curves represent simulations of changes in
affinity. A left-shifted binding curve (red) indicates a decrease in KD1, and an
increase in apparent binding affinity. A right-shifted curve (blue) indicates an
increase in KD1, and a resultant decrease in apparent binding affinity.
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Probe separation distance (R) for the SERCA-PLB regulatory complex
was calculated using the Förster equation (Förster 1948), R = (RO) [(1/E) − 1)1/6],
where RO is the Förster radius, and E is the measured FRETmax. Intrapentameric
probe separation distance was calculated from FRETmax using a MatLab
application (Kelly et al. 2008), assuming a ring-shaped oligomer (Li et al. 1999,
Robia, Flohr, and Thomas 2005, Runnels and Scarlata 1995), with a subunit
number of 5 (pentamer). For the R9C-PLB FRET experiments, the acceptor
molar fraction was 0.89 for the WT-PLB pentamer and 0.92 for the R9C-PLB
pentamer. For the C-terminal mutants FRET experiments, the average acceptor
molar fraction was calculated to be 0.92 ± 0.01 for WT-PLB, 0.89 ± 0.02 for the
alanine substitution mutants and 0.88 ± 0.01 for the truncation mutants.
Previously, we estimated non-specific FRET to be 4%, as determined from
competition with unlabeled PLB or with a fluorescently-labeled PLB that is unable
to participate in FRET (Kelly et al. 2008, Ha et al. 2011). We quantified nonspecific FRET by calculating the apparent FRET efficiency for cells coexpressing Cer-WT-PLB and YFP-WT-PLB as shown in Fig. 7. The results
indicated that the apparent FRET efficiency for cells expressing Cer-WT-PLB and
YFP-WT-PLB was 48.8% (Fig. 7, WT). In contrast, the control cells expressing
non-interacting proteins Cer and YFP exhibited very low apparent FRET of 3.7%
(Fig. 7, Control). In addition, we performed another control experiment and
estimated apparent FRET of 0.85% for cells expressing Cer-PLB without any
acceptor. For estimation of probe separation distances for both the pentamer and
regulatory complex, the Förster radius of 49.8 Angstrom (Å) was used for the Cer
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-YFP pair (Gadella 2009) and 4% non-specific FRET was subtracted from the
measured FRETmax values.
IonOptix Data Acquisition and Analysis
Adult rabbit left ventricular cardiomyocytes expressing YFP-WT-PLB or
YFP-R9C-PLB were loaded with 10 μM Indo-1 AM Ca2+ dye (Invitrogen Inc.,
France) for 20 minutes at room temperature, and washed with fresh Tyrode
solution (135 mM NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM d-Glc, 10
mM HEPES, pH 7.4). Following this, cardiomyocytes were electrically stimulated
with 20V, 6 ms pulse duration, at increasing pacing frequencies of 0.3 Hz, 0.5
Hz, and 0.75 Hz. Ca2+ transients and sarcomere shortening were recorded
(IonOptix, Milton, MA) before and after 10 minute incubation with 100 nM
isoproterenol (iso). Ca2+ transient recordings were obtained by measuring
fluorescence intensity at excitation and emission wavelengths of 340 and
405/485 nm respectively and analyzed using the IonOptix software.
SDS PAGE and Western Blot Analysis
Total cell lysates were obtained by washing AAV-293 cells expressing
Cer-tagged PLB-WT and mutant constructs with phosphate-buffered saline (PBS;
pH 7.4), and treating with Hunter’s buffer on ice (25mM HEPES, pH 7.4, 150 mM
NaCl, 1.5 mM MgCl2, 1mM EGTA, 1% Na deoxycholate, 1% Triton X 100, 0.1%
SDS, 10% glycerol, and complete protease inhibitor cocktail [Santa Cruz]). The
lysates were sonicated and centrifuged at 14,000 rpm at 4°C for 30 min, and the
supernatants were boiled in Laemmli buffer containing beta-mercaptoethanol
prior to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
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and western blotting analysis. The proteins were transferred onto the PVDF
membranes, which were blocked for 1 h with 5% milk in TBS-0.05% Tween 20
(TBST). The membrane was washed with TBST and incubated with anti-PLB
mouse monoclonal primary antibody 2D12 (Abcam) at a dilution of 1:2000 at 4°C
overnight. After washing with TBST, the membrane was incubated with
fluorescent

secondary

antibody,

Alexa

Fluor

532

goat-anti-mouse

IgG

(Invitrogen) at a dilution of 1:10,000 at room temperature for 1 h. The membrane
was then scanned using Typhoon Trio with the following settings of acquisition
mode: Fluorescence; Emission Filter: 555 BP 20 R6G, HEX, AF532; Laser:
Green-532; PMT: 425; Pixel size: 100 microns. The same samples were
subjected to western blot analysis using anti-GFP antibody to detect mCer-PLB
and anti-β-actin antibody to act as a loading control.
Immunofluorescence Microscopy
After a 48 hour period of adenoviral infection, cardiomyocytes in culture
expressing CFP-R9C-PLB were fixed in 4% paraformaldehyde solution for 15
minutes, washed with PBS and permeabilized using 0.2% Triton-X-100 for 10
minutes at room temperature. The cells were blocked with 1% bovine serum
albumin for 30 min, and then incubated with the anti-PLB mouse monoclonal
2D12 antibody at 1:500 dilution. The cells were incubated with Alexa Fluor 532
goat anti-mouse antibody at 1:1000 dilution for 1 hour at room temperature. The
coverslips were washed with PBS and mounted on the microscopic slides using
mounting media (Vector laboratories). After immunofluorescence staining, cells
were subjected to confocal imaging using an inverted Leica TCS SP5 confocal
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microscope with 63× water immersion objective. CFP and Alexa Fluor 532 were
sequentially excited at 458 nm and 543 nm to detect the localization of
exogenous CFP-R9C-PLB and endogenous WT-PLB respectively.
Fluorescence Microscopy
To quantify the membrane localization of PLB, cells were cotransfected
with Cer-SERCA and YFP-PLB-truncation mutants at a 1:1 ratio and subjected to
confocal imaging using an inverted Leica TCS SP5 confocal microscope with a
63× water immersion objective. Cer and YFP were sequentially excited at 458
nm and 514 nm respectively. The membrane partitioning of YFP-PLB-truncation
mutants was evaluated by comparison with Cer-SERCA. The apparent
membrane partition coefficient for PLB and all the truncation mutants of PLB was
quantified as the ratio of YFP fluorescence intensity in the endoplasmic reticulum
(ER) region (perinuclear) to nuclear fluorescence intensity. Solubilization of PLB
was also quantified using widefield fluorescence microscopy to measure the loss
of fluorescence from cells permeabilized with 100 μg/ml saponin. Cell
impermeant

nuclear

stain

propidium

iodide

(PI)

was

used

to

verify

permeabilization. Cells expressing Cer-SERCA and YFP-PLB truncation mutants
were preincubated with 2 μg/ml PI and imaged for Cer, YFP, and PI fluorescence
during the course of saponin permeabilization.
Statistical Analysis
Errors are reported as standard error of the mean and statistical
significance was evaluated using a standard unpaired two-tailed type 2 Student's
T test, where p value < 0.05 was considered significant.

CHAPTER III
ACUTE INOTROPIC AND LUSITROPIC EFFECTS OF CARDIOMYOPATHIC
R9C MUTATION OF PHOSPHOLAMBAN
In this study, we investigated the acute physiological consequences of
R9C-PLB mutation on Ca2+ kinetics and contractility using adenoviral delivery of
R9C-PLB to adult rabbit cardiomyocytes. Rabbit ventricular cardiomyocytes are
particularly good models of human cardiac Ca2+ cycling (Hasenfuss 1998,
Pattison et al. 2008, Bers 2002) compared to mice. We reasoned that acute
expression

might

reveal

new

mechanistic

information

about

R9C

pathophysiology, complementing previous transgenesis studies that focused on
long-term effects of R9C mutation. To specifically test the consequence of R9C
mutation for PLB oligomerization, we modulated PLB oligomerization affinity with
mutations of three transmembrane Cys residues to Ser (SSS) (Fig. 5B). This set
of mutations has been proposed to abolish PLB oligomerization (Ceholski et al.
2012), and could isolate the effect of R9C from other determinants of PLB
oligomerization.
R9C-PLB Exerts a Positively Inotropic and Positively Lusitropic Effect in
Cardiomyocytes
We subjected AAV-293 cells expressing Cer-tagged PLB-WT and mutant
constructs to SDS PAGE followed by western blot analysis. The results indicated
that the commercially available PLB-2D12 antibody recognized both WT-PLB
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and SSS-PLB, but not R9C-PLB or R9C+SSS-PLB (Fig. 8). This observation is
likely due to the fact that the R9C mutation is within the epitope region for the
PLB-2D12 antibody (between amino acid residues 9-17 of canine PLB). Since
the R9C-PLB and R9C+SSS-PLB constructs were Cer-tagged, they could be
easily detected by GFP antibody (Fig. 8). β-Actin served as a loading control
(Fig. 8). Furthermore, adenoviral delivery of R9C-PLB tagged with CFP or YFP
to enzymatically isolated adult rabbit cardiac myocytes yielded fluorescence
detectable by confocal or widefield fluorescence microscopy after 48 hours in
culture. We observed PLB localization in the perinuclear region and in
longitudinal streaks and cross-striations (Fig. 9A) as previously observed for
fluorescently labeled wild-type (WT)-PLB (Bidwell et al. 2011). The fluorescence
pattern is consistent with localization in the sarcoplasmic reticulum (SR), and is
similar to that previously observed for fluorescently labeled SERCA2a (Bidwell et
al. 2011, Pallikkuth et al. 2013). In order to compare the localization of
exogenous

R9C-PLB

with

endogenous

WT-PLB,

we

performed

immunofluorescence microscopy using anti-PLB mouse monoclonal 2D12
antibody. We observed that the localization of endogenous WT-PLB labeled with
Alexa Fluor 532 secondary antibody was similar to CFP-R9C-PLB (Fig. 9A), and
demonstrates that exogenous PLB does not fully replace endogenous PLB.
Thus, the present experimental system may be considered a model of
heterozygous expression of R9C-PLB against a WT- PLB background. R9C-PLB
and WT-PLB signals were not completely colocalized, as evidenced from
subcellular regions with relatively more CFP or Alexa Fluor 532 signal (Fig. 9A).
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This is likely due to non-uniform decoration of the cardiac myocytes by the
primary or secondary antibodies used to visualize endogenous WT-PLB.
Chronic R9C-PLB expression in transgenic mouse models results in
depressed Ca2+ handling and decreased myocyte contractility (Schmitt et al.
2009, Schmitt et al. 2003). To determine the physiological effect of acute R9CPLB expression after adenoviral delivery, we compared Indo-1 Ca2+ transients
and sarcomere shortening kinetics of myocytes expressing YFP-R9C-PLB or
YFP-WT-PLB at increasing pacing frequencies of 0.3 Hz, 0.5 Hz, and 0.75 Hz
(Fig. 9B, 9C). R9C-PLB-expressing myocytes showed markedly accelerated
Ca2+ handling as evidenced from an elevated peak Ca2+ and decreased Ca2+
transient duration compared to WT-PLB-expressing myocytes (Fig. 9B). There
was a corresponding increase in contractility for R9C-PLB-expressing myocytes
as evidenced from an increased peak amplitude and decreased peak duration
compared to WT-PLB-expressing myocytes (Fig. 9C). The baseline for Ca2+
transients and sarcomere length was not significantly different between WT-PLBand R9C-PLB-expressing cells. We noted that the resting sarcomere length of
the cultured myocytes was shorter than the 1.7-1.8 m value observed for freshly
isolated cardiac myocytes as a consequence of two days of maintenance in
culture. Ca2+ transient parameters and sarcomere shortening data are
summarized in Fig. 10 and Tables 1 and 2. R9C-PLB expressing cells were
significantly hyperdynamic compared to those expressing WT-PLB, with a 28%
decrease in the Ca2+ transient decay time (Fig. 10A), and a 20% decrease in the
peak duration of the Ca2+ transient (Fig. 10C). The corresponding lusitropic effect
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was evidenced by faster sarcomere relengthening, with a 23% decrease in the
relaxation velocity time for R9C-PLB-expressing myocytes (Fig. 10B) and a 19%
decrease in the peak duration of the sarcomere shortening transient compared to
WT-PLB-expressing myocytes (Fig. 10D).
R9C-PLB Exhibits Blunted Sensitivity to Frequency Potentiation and βAdrenergic Stimulation
Increasing the pacing frequency enhances cardiac contractility by
increasing the rate of SR Ca2+ release, also known as ‘force-frequency
relationship’ (Endoh 2004, Janssen and Periasamy 2007, Janssen 2010).
Frequency potentiation also accelerates cardiac relaxation by increasing the rate
of SR Ca2+ uptake, also described as ‘frequency-dependent acceleration of
relaxation’ (Janssen and Periasamy 2007, Janssen 2010, Varian and Janssen
2007). Interestingly, while WT-PLB-expressing cells showed the expected
increase in Ca2+ uptake and sarcomere relaxation rate with rapid pacing, there
was very little additional enhancement of Ca2+ uptake or relaxation of R9C-PLBexpressing cells as pacing frequency increased from 0.3 to 0.75 Hz (Fig. 9B, 9C,
Fig. 10). The data suggest that the R9C mutation of PLB maximally stimulates
Ca2+ uptake and cell relaxation, and additional stimulation by increased pacing
frequency provides only a marginal additive effect. The blunted frequency
response of the R9C-PLB-expressing cells is highlighted in Fig. 10A with a
dashed red line, which may be compared to WT-PLB, dashed black line. We also
observed a 52% increase in the amplitude of the peak of the Ca2+ transient in
R9C-PLB-expressing cells compared to WT-PLB (Fig. 10E), suggesting an
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release resulted in

positive inotropy, with a 71% increase in myocyte fractional shortening (Fig.
10F). Most of the Ca2+ handling and sarcomere shortening parameters quantified
here and in Tables 1 and 2 showed the same pattern of a blunted frequency
response, suggesting that R9C-PLB expressing cells were already maximally
stimulated, with little additional capacity for frequency dependent lusitropy or
inotropy.
Similarly, we observed decreased responsiveness of R9C-PLB expressing
cells to -adrenergic stimulation with isoproterenol (iso). While WT-PLB
expressing cells showed a robust increase in peak Ca2+ and a faster Ca2+
transient decay in response to iso (Fig. 11A), R9C-PLB expressing cells were
already hyperdynamic and iso caused no additional increase in Ca2+ handling
kinetics (Fig. 11B). Instead, we observed a modest decrease in peak Ca2+,
possibly as a result of Troponin I phosphorylation or increased Na+-K+-ATPase
activity. Fig. 11C, 11D show the corresponding effects of iso stimulation on
sarcomere shortening for WT-PLB and R9C-PLB expressing cells, respectively.
Overall, the acute physiological effect of the R9C mutation of PLB is positively
inotropic and lusitropic, consistent with a model of disinhibition of SERCA as a
result of a loss of inhibitory function for R9C-PLB (Schmitt et al. 2003, Schmitt et
al. 2009, Ceholski, Trieber, and Young 2012, Ha et al. 2011).
R9C-PLB Increased Oligomerization and Decreased SERCA-Binding
Despite Pentamer-Destabilization by SSS Mutation
A previous study in our lab has attributed the loss-of-function character of
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R9C to increased PLB oligomerization secondary to oxidative crosslinking of the
introduced cysteine in adjacent protomers of PLB pentamers (Ha et al. 2011). To
investigate the change in PLB oligomerization energetics in more detail, we
compared

the

relative

effects

of

R9C

mutation

with

substitution

of

transmembrane Cys residues 36, 41 and 46 with Ser (SSS) (Fig. 5B). The SSS
mutation is known to destabilize the PLB pentamer (Fujii et al. 1989), and this
mutant runs as a monomer in polyacrylamide gel electrophoresis (PAGE)
(Ceholski et al. 2012). We performed E-FRET (Zal and Gascoigne 2004)
measurements of large populations of AAV-293 cells (500-1500 cells per
experiment). We observed a 12% increase in the average intrapentameric FRET
for R9C-PLB compared to WT (Table 3), consistent with previous observations
(Ha et al. 2011). SSS-PLB also exhibited FRET, suggesting that despite running
as a monomer on SDS-PAGE (Ceholski et al. 2012), the SSS mutant can form
pentamers in the membrane environment. However, SSS average FRET was 5%
less than WT, suggesting that oligomerization was weakened by the mutations of
the transmembrane domain (Table 3). To quantify PLB-PLB binding affinity, we
used an in-cell binding assay described previously (Abrol et al. 2014, Bidwell et
al. 2011, Ha et al. 2011, Hou and Robia 2010, Hou, Kelly, and Robia 2008, Kelly
et al. 2008). The heterogeneous protein expression level of the transiently
transfected population of cells provided insight into the dependence of FRET on
protein concentration. FRET increased with protein expression up to a maximal
level (Fig. 12) that reflected the intrinsic FRET of the pentamer (FRETmax). The
concentration of protein that yielded half- maximal FRET is a measure of the
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apparent dissociation constant (KD1) of the PLB pentamer. Thus, the binding
curve reveals the relative contributions of oligomerization and protein structure
changes to the observed increase in intrapentameric FRET with mutations. As
previously observed, R9C increased FRETmax, suggesting that the R9C-PLB
pentamer had a more compact conformation (Fig. 12A, Table 3). This
observation is consistent with a model in which disulfide crosslinking of
introduced Cys residues on adjacent protomers brings the cytoplasmic domains
and Cer/YFP fusion tags into closer proximity. The R9C mutation also increased
the affinity of PLB oligomerization, as shown by a left shift of the binding curve of
R9C (Fig. 12A), accounting for 55% decrease in KD1 (Fig. 12B) compared to
WT. In contrast, destabilization of the PLB pentamer by SSS right-shifted the
binding curve compared to WT (Fig. 12A). Notably, addition of the R9C mutation
increased the stability of the SSS-PLB pentamers, as shown by a left shift of the
R9C+SSS-PLB binding curve (Fig. 12A), and a 29% decrease in KD1 (Fig. 12B)
relative to SSS. The data are summarized in Fig. 12B and Table 3. We conclude
that R9C enhances PLB oligomerization both in WT and SSS background,
indicating that R9C potentiates PLB oligomerization even for weakly oligomeric
variants.
Increased oligomerization of R9C-PLB had the predicted consequence for
binding of R9C-PLB to SERCA. Since SERCA is regulated by monomeric PLB
(MacLennan and Kranias 2003, Kranias and Hajjar 2012), depletion of the
monomer pool by increased oligomerization was expected to decrease PLBSERCA binding. Indeed, we observed a right shift of the R9C-PLB-SERCA
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binding curve (Fig. 12C), and a 29% increase in the apparent dissociation
constant KD2 (Fig. 12D) compared to WT. The data are summarized in Fig. 12D
and Table 3. The effect of the SSS mutation was less clear. We expected
increased binding of SSS to SERCA vs. WT, but because the binding curve did
not saturate, we could not accurately quantify FRETmax and KD2 for this mutant.
The failure to saturate may be due to increased non-specific FRET for the more
monomeric PLB species (King et al. 2014). While the absolute value of KD2 is not
certain, we did observe the expected relative change with the addition of R9C.
Specifically, the combined mutant R9C-SSS showed a right-shifted binding curve
relative to SSS (Fig. 12C), with an increase in KD2 relative to SSS (Fig. 12D).
We also observed a decrease in FRETmax for R9C relative to WT (Fig. 12C,
Table 3). This parameter represents the intrinsic FRET efficiency of the bound
PLB-SERCA regulatory complex. A decrease in FRETmax suggests that a change
in the conformation of the regulatory complex that moves the FRET acceptor
(YFP) farther from the donor (Cer). The functional significance of this structure
change is not clear, but it is reminiscent of the decrease in PLB-SERCA FRETmax
observed with phosphomimetic mutations of PLB (Hou, Kelly, and Robia 2008).
Overall, we conclude that increased PLB oligomerization reduced SERCA
regulation, accounting for the observed hyperdynamic Ca2+ handling of the R9CPLB expressing cardiac myocytes.
R9C-PLB Exhibits Increased Sensitivity to Oxidative Stress
To determine the role of Cys oxidation in the observed effect of R9C
substitution on PLB oligomerization, cardiac myocytes were treated with 100 M
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H2O2 (Schroder and Eaton 2008) during observation by fluorescence imaging.
Widefield fluorescence microscopy did not reveal a change in the localization of
PLB (not shown), and we did not observe any aggregation of protein after
treatment with H2O2. However, oxidation significantly increased in the relative
emission of YFP/CFP (with CFP excitation). The observed 14% increase in
FRET ratio is evident in Fig. 13A (+ H2O2) as a transition to warmer colors, and
is quantified in Fig. 13B. There was no change in FRET ratio for cardiac
myocytes expressing WT CFP/YFP-PLB (Fig. 13B), consistent with previous
observations in AAV-293 cells (Ha et al. 2011). To differentiate the effect of
oxidation of cytoplasmic domain Cys-9 from the transmembrane cysteines, we
measured PLB-PLB FRET after mutating the three transmembrane cysteines to
serine residues (SSS) (Fig. 5B). A quantitative comparison of average FRET
efficiency of these mutants in AAV-293 cells showed that the R9C-PLB is already
increasingly oligomeric before the addition of H2O2 (29% FRET vs. 26% for WT),
and oxidation further increased FRET to a maximum of 35% (Fig. 13C, red). WTPLB intrapentameric FRET does not increase with oxidation (Fig. 13C, black).
SSS (Fig. 13C, green) is likewise unresponsive to H2O2, and average FRET is
reduced compared to WT consistent with destabilization of SSS pentamers.
Interestingly, the combination of R9C+SSS (Fig. 13C, blue) yields an
intermediate level of FRET that is markedly increased by H2O2 oxidation, up to
the same maximal 35% FRET efficiency observed for R9C-PLB. The data
suggest that oxidation of R9C on the native transmembrane domain or the SSS
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background results in maximal oligomerization of PLB regardless of the initial
level of oligomerization.
We conclude that the primary mechanism of R9C pathology is a
phosphomimetic effect of PLB cys-9 oxidation, manifested as increased
oligomerization and a change in the structure of the PLB-SERCA regulatory
complex. The resultant decrease in the availability of monomeric PLB reduces
SERCA regulation, accounting for the inability to respond to frequency
potentiation and β-adrenergic stimulation, and eventual heart failure.

CHAPTER IV

PHOSPHOLAMBAN C-TERMINAL RESIDUES ARE CRITICAL
DETERMINANTS OF THE STRUCTURE AND FUNCTION OF THE CALCIUM
ATPASE REGULATORY COMPLEX
We have previously shown that truncating the C-terminus of PLB midway
through its TM domain by L39X mutation greatly reduced PLB oligomerization
and SERCA binding (Kelly et al. 2008). In the present study, we investigated the
role of C-terminal residues of PLB in membrane anchoring, localization, PLB
oligomerization, and SERCA regulation. The results provide insight into the
structural and functional consequences of mutating or truncating the TM domain,
and reveal an unexpected role for PLB C-terminal residues in determining the
quaternary conformation of the PLB-SERCA regulatory complex.
Functional Role of C-Terminal Residues in Regulation of SERCA Function
To investigate the role of C-terminal residues (Fig. 5C) in determining the
inhibitory potency of PLB, we reconstituted SERCA with wild-type (WT) or with Cterminal Ala substitutions or truncations of PLB. Previous Ala substitution of
individual residues in this region (Val49-Met-Leu-Leu52) revealed little change in
inhibitory potency for L52A or M50A mutants and gain-of-function for the L51A
and V49A mutants (Trieber, Afara, and Young 2009). C-terminal alanine
substitution of all four residues 49-52 resulted in gain of PLB regulatory function
and there appeared to be a nexus for gain-of-function at Val49 for both individual
48
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and multiple alanine substitutions (Abrol et al. 2014). In contrast, deletion of
these same residues, which shortens the PLB TM helix, resulted in a loss of
regulatory function (Abrol et al. 2014). The data indicate that the C-terminal
residues of PLB are important determinants for SERCA inhibition and that even
small deletions have a particularly deleterious effect.
Ala-Substitution Mutations of PLB C-Terminal Residues Alter PLB
Pentamer Structure and Oligomerization Affinity
To investigate the role of the C-terminal residues in determining the
structure and affinity of the PLB pentamer, we quantified intraoligomeric FRET
for mixed pentamers of Cer- and YFP-PLB. Replacement of C-terminal residues
with a single Ala substitution generally decreased average FRET efficiency
compared to WT (Fig. 14A, Table 4). To determine the relative contributions of
pentamer structure change or a change in the degree of PLB oligomerization to
the observed changes in average FRET, we performed an in-cell binding assay
in which FRET is quantified from a heterogeneous population of transfected cells
expressing a wide range of concentrations of PLB (Abrol et al. 2014, Bidwell et
al. 2011, Ha et al. 2011, Hou and Robia 2010, Hou, Kelly, and Robia 2008, Kelly
et al. 2008). Fig. 14B shows that cells expressing high concentrations of PLB
exhibited higher FRET than cells with a low expression level. FRET increased
with [protein] to a maximum level (FRETmax), and this relationship was welldescribed by a hyperbolic fit. FRETmax was modestly increased for L52A, the last
residue of the helical TM domain of PLB (Fig. 14C, red). L51A also shows a
small increase in FRETmax (Fig. 14C, blue), but this value must be viewed with
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caution as the FRET vs. [protein] relationship never achieves maximal FRET for
this mutant (Fig. 14B).

A failure to saturate is often observed for highly

monomeric mutants of PLB as a result of increased non-specific FRET between
non-interacting monomers. Thus, the fitted value of FRETmax is compromised by
this non-specific FRET contribution. Consistent with this non-saturating FRET
relationship, we observed a right-shift of the L51A FRET vs. [protein] binding
curve (Fig. 14B), suggesting a decreased oligomerization affinity. The PLB
dissociation constant (KD1) was significantly increased for all Ala mutants,
indicating a decreased oligomerization affinity. We observed a >1.5-fold increase
in KD1 for L52A and a >4-fold increase in KD1 for L51A compared to WT (Fig.
14D), as quantified from a hyperbolic fit of the data in Fig. 14B. Next, moving up
the TM helix, we investigated the effect of an M50A substitution. This mutant
showed no change in pentamer structure (Fig. 14C), but a 1.5-fold increase in
KD1 (Fig. 14D), as seen from the right-shifted binding curve of M50A (Fig. 14B,
pink) relative to WT (Fig. 14B, black) without a change in maximal FRET. The
data suggest that the mutant destabilizes oligomerization without altering the
structure of the pentamer. Finally, V49A showed a very large decrease in
FRETmax (Fig. 14C) consistent with an increase in the average separation of Nterminal fluorescent tags of 3Å, and a 40% increase in the affinity of
oligomerization for this mutant (Fig. 14D). The results are summarized in Table
4. The data demonstrate that the position of the fluorescent protein, fused to the
N-terminus (on the cytoplasmic side of the bilayer), is altered by substitution of
Leu or Val with Ala at remote sites in the C-terminus (on the luminal side of the
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bilayer).
Mutation of

PLB

C-terminal

Residues

Alters

Regulatory Complex

Quaternary Structure and PLB-SERCA Binding Affinity
To determine how N-terminal residues affect the structure and affinity of
the PLB-SERCA regulatory complex, we measured FRET from the N-terminal
Cer tag on SERCA2a to YFP-PLB. Fig. 15A shows that average FRET was
increased by L51A, and V49A mutants.

In-cell binding assays revealed the

relative changes in binding affinity and structure for these mutants (Fig. 15B). As
observed in the oligomerization binding assay (Fig. 14B), L51A showed poor
saturation (Fig. 15B) consistent with non-specific FRET from an increased
population of monomers (increased KD1, Fig. 14D). Thus, the FRETmax value for
this mutant is not a clear representation of regulatory complex structure. The
other mutant with a significant change in SERCA-binding was V49A which
showed a 23% increase in FRETmax, suggesting a very compact regulatory
complex conformation, and a 73% decrease in dissociation constant KD2 (Fig.
15D), indicating an increase in the apparent affinity for SERCA. The observed
increase in SERCA binding is in harmony with previous reports that suggest
increase inhibitory potency for this mutant (Chen et al. 2006, Akin et al. 2013).
C-terminal Residues are Critical for PLB Membrane Localization
A previous study in our lab observed solubilization of PLB by the human
heart failure missense mutation L39X (Kelly et al. 2008), and we anticipated that
smaller C-terminal deletions of the PLB TM domain could likewise disrupt
anchoring of the protein in the membrane. To verify this, relative partitioning of
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PLB in the aqueous cytoplasm and the ER bilayer was assessed with confocal
microscopy. While single Ala substitutions did not significantly alter the
localization of PLB expressed in AAV-293 cells (not shown) we observed a
significant degree of mislocalization of PLB with C-terminal truncations, as shown
in Fig. 16. An overlay of images revealed co-localization of Cer-SERCA (Fig.
16A, cyan), and YFP-WT-PLB truncation mutants (Fig. 16A, yellow).
Successive truncations caused mislocalization of PLB to the cytoplasm and
nucleus (Fig. 16A), as quantified from the apparent membrane partition
coefficient [ratio of ER (perinuclear) fluorescence to nuclear fluorescence)] (Fig.
16B). Interestingly, deleting only one C-terminal residue of PLB of the 22 TM
domain residues was sufficient to cause partial loss of ER membrane
localization. Deletion of more than 4 residues nearly abolished ER localization.
Cer-SERCA localization was not changed (Fig. 16A).
To determine whether the observed mislocalization was due to
solubilization of PLB, we selectively permeabilized the plasma membrane of cells
using saponin (Kelly et al. 2008). Cer-SERCA ER localization was not changed
during the course of saponin permeabilization, but truncated YFP-PLBL39X rapidly
diffused out of the cell into the surrounding medium (Fig. 16C). As expected, the
degree of PLB solubilization depended upon the severity of the PLB truncation.
Longer PLB constructs left residual fluorescence in cells after permeabilization
(Fig. 16D, 17A-17H). Loss of PLB truncation mutants after saponin
permeabilization is summarized in Fig. 16D, and Fig. 17A-17H. We observed a
progressive increase in solubilization of PLB upon subjecting the C-terminus of
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ER membrane localization. Scale bar = 5 µm. (B) Successive truncations caused
a progressive decrease in apparent membrane partition coefficient (ratio of ER
fluorescence/nuclear fluorescence). Error bars represent cell-to-cell variability; an
average of 40 to 50 cells were used for each mutant. (C) Plasma membrane
permeabilization resulted in complete loss of YFP-PLBL39X, no change in CerSERCA fluorescence, and increased propidium iodide staining. (D) Diffusion of
YFP-PLB truncation mutants from cells after saponin permeabilization. (E)
Successive truncations lead to decrease in partition equilibrium constants
estimated either by localization (KL) or permeabilization (KP). AU: arbitrary units.
(F) There was good agreement between KL and KP.
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PLB to truncation mutations (Fig. 17). Cells coexpressing Cer-SERCA and YFPPLB WT or truncation constructs including L52X, L51X, M50X, V49X, L48X,
I38X, or I33X were selectively permeabilized as shown with propidium iodide.
Cer-SERCA fluorescence was unchanged, and propidium iodide staining for all
the truncation constructs was increased indicating efficient permeabilization (Fig.
17A-17H). We observed that the more residues that were truncated from the Cterminus of PLB, the greater the degree of solubilization as indicated by
progressive decrease in YFP-PLB fluorescence after saponin permeabilization
(Fig. 17A-17H).
As expected, molecular dynamic simulation studies of the PLB pentamer
structure revealed that the C-terminal domain of the WT protein was retained in
the bilayer, while the C-terminal domain of the L39X mutant translocated out of
the bilayer within a few ns and was fully solubilized by the end of the simulation
(Abrol et al. 2014). Furthermore, we subjected mCer-PLB WT and truncation
mutant protein samples to SDS PAGE followed by western blot analysis using
anti-GFP antibody. The results of western blot analysis showed the expected
mobilities for truncation mutants relative to full length PLB-WT (Fig. 18),
indicating that the observed solubilization of PLB truncation mutants is not due to
proteolysis. The dual bands were observed for the tagged monomer due to
differential migration of folded and aggregated GFP fusion proteins. Additionally,
the apparent membrane localization of PLB mutants was quantified by dividing
the ER fluorescence (membrane-bound PLB) by the total fluorescence (nuclear +
ER), or by dividing the residual PLB fluorescence after saponin permeabilization
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by total PLB fluorescence before permeabilization. Partition equilibrium
constants estimated by the localization and permeabilization methods were
referred to as KL and KP, respectively. Truncations of PLB C-terminus decreased
both KL and KP (Fig. 16E). The alternative methods were in good agreement
with a linear relationship between KL and KP (Fig. 16F), though KL exhibited a
non-zero offset due to the contribution of non-membrane bound PLB to the ER
fluorescence signal. The data are summarized in Table 5.
C-terminal Residues are Also Important for PLB Oligomerization
Deletion of any of the PLB C-terminal residues greatly decreased PLBPLB binding in live cells, as quantified by FRET between Cer and YFP fused to
PLB N-termini. Fig. 19A shows that PLB average intrapentameric FRET
efficiency was progressively decreased upon truncating the C-terminal residues
of PLB. Truncation of 4 C-terminal residues of the 22 amino acid TM domain of
PLB (V49X) resulted in a 44% decrease in the average FRET efficiency (Fig.
19A). FRET was largely abolished by truncation of more than 4 residues. Thus,
the FRET data underscore the importance of Val-49 in determining PLB
structure/function. In particular, we used the in-cell binding assay to quantify the
relative contributions of altered binding and pentamer conformational change to
the observed FRET change. Truncating the C-terminal residues of PLB resulted
in a progressive decrease in PLB intrapentameric FRET efficiency as shown in
Fig. 19B. FRETmax was unchanged for L52X, L51X, M50X, or V49X compared to
WT, indicating that PLB quaternary structure was not significantly affected upon
truncating up to 4 C-terminal residues (Fig. 19C, Table 4). This is in contrast
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with Ala substitution mutants, several which profoundly affect PLB oligomer
structure (Fig. 15C, Table 4). Truncating more than 4 residues of the 22 amino
acid long TM domain significantly decreased FRETmax. We attribute this to loss of
membrane anchoring, rather than a change in pentamer structure. C-terminal
truncations also progressively increased the pentamer dissociation constant KD1,
indicating a decrease in the affinity of PLB oligomerization (Fig. 19D). Truncating
only one C-terminal residue resulted in 2-fold increase in KD1 compared to WT,
and binding affinity worsened with each additional residue that was deleted. We
quantified a 12-fold increase in KD1 for V49X compared to WT indicating a
decrease in oligomerization affinity. The affinity for the shortest truncation
mutants was too low to measure. The data are summarized in Table 4. PLB-PLB
binding is reduced by loss of C-terminal residues, and this loss of binding
parallels the loss of bilayer anchoring. Predictably, colocalization of PLB
protomers in the membrane is prerequisite to oligomerization.
PLB C-terminal Residues are Critical for Regulatory Complex Structure
and Function
To determine how the C-terminal truncation of PLB affects its interaction
with SERCA, we quantified FRET from Cer-SERCA to YFP-tagged truncation
mutants of PLB. Surprisingly, truncation of up to 4 C-terminal residues (out of 22
residues in the TM domain) significantly increased SERCA-PLB FRET efficiency
(Fig. 20A, 20B). This was not due to increased binding of PLB to SERCA since
KD2 predictably increased with deletion of C-terminal residues (decreased
binding affinity) (Fig. 20D). Truncating only one residue resulted in a nearly 2-fold
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increase in KD2, truncating 4 residues (V49X) caused an approximately 2.5-fold
increase in KD2, and removing more than 4 residues resulted in a binding affinity
that was too low to measure (Fig. 20D). It appears that despite the decrease in
binding of truncated PLB for SERCA, the average FRET is still increased
because the remaining regulatory complexes have a higher intrinsic FRET
efficiency (FRETmax). Deleting only one C-terminal residue of PLB resulted in a
1.2-fold increase in FRETmax, and truncating 4 C-terminal residues (V49X)
resulted in a greater than 2-fold increase in FRETmax (Fig. 20C), consistent with
an increase in the average separation of N-terminal fluorescent tags of 11.3 Å.
The data suggest that that C-terminal truncations alter the structure of
PLB:SERCA regulatory complex (Table 4). The structural effect of C-terminal
deletions mimics the regulatory complex conformational change due to 49A (Fig.
15C), which also decreased the separation of fluorescent protein tags positioned
atleast 40 Å away on the other side of the bilayer.
We conclude that the luminal residues nearest the PLB C-terminus are
critical for membrane anchoring and quaternary structure determination of both
the PLB pentamer and the PLB-SERCA regulatory complex. The loss of
membrane registration restraint by C-terminal residues (especially V49) causes
displacement of PLB to an alternative position on SERCA. The data suggest
multiple modes of binding for PLB on SERCA, and are compatible with a model
in which PLB binds to the canonical inhibitory binding site and an additional novel
site as discussed in Fig. 21, Chapter V.

CHAPTER V

DISCUSSION
In the cardiac muscle, PLB plays a predominant role in the regulation of
Ca2+ homeostasis and contractility (MacLennan and Kranias 2003, Kranias and
Hajjar 2012). The equilibrium between PLB homopentamer and monomer plays a
critical role in regulating SERCA function and physiology of heart muscle (Robia
et al. 2007, Kranias and Hajjar 2012) Notably, several hereditary mutations of
PLB have been identified in humans to cause DCM and HCM, eventually
resulting in heart failure (Medeiros et al. 2011). Using live cells, we studied the
structural and functional consequences of two naturally-occurring human heart
failure mutants of PLB including R9C and L39X. In addition, to identify the role of
TM domain of PLB in membrane anchoring, PLB oligomerization, and SERCA
regulation, we subjected the C-terminus of PLB to alanine substitutions and
truncation mutations. In particular, we investigated the effect of these mutations
on membrane localization, structure and oligomerization affinity of the PLB
pentamer, structure and binding affinity of SERCA-PLB regulatory complex and
function of SERCA-PLB regulatory complex.
PLB Mutations and Membrane Localization
PLB is an integral SR membrane protein that binds and inhibits cardiac
Ca2+ pump, SERCA2a. We reasoned that localization of PLB in the membrane is
67
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a prerequisite for PLB oligomerization. Two of the most common human
mutations in PLB linked to heart failure involve a single residue deletion (Arg14deletion) (DeWitt et al. 2006, Haghighi et al. 2006, Posch et al. 2009) and a
multiple residue truncation (Leu39-stop) (Haghighi et al. 2003, Chiu et al. 2007,
Landstrom et al. 2011). Since a large portion of the C-terminus of PLB is missing
in this latter truncation variant, we wished to understand the comparative effects
of mutations and truncations in this region. We studied the role of C-terminal
residues in determining membrane localization of PLB by subjecting the Cterminus of PLB to alanine substitution and truncation mutations. While
substitutions appeared to be benign for localization, we observed that C-terminal
deletions including heart failure mutant L39X decreased PLB membrane
anchoring (Fig. 21B, iv), releasing a fraction of the PLB into the cytoplasm,
where it can no longer participate in regulatory interactions. Although SERCA
coexpression has been shown to improve localization of sarcolipin truncation
mutants (Gramolini et al. 2004), PLB localization was not improved by
coexpression of SERCA in the present work or in previous studies (Butler et al.
2007, Stenoien et al. 2007). Previously, the C-terminal region of PLB region has
been shown to be important for subcellular trafficking, as increasing the length of
the TM domain of PLB by adding 4 extra leucine residues to the C-terminus
resulted in mistargeting to the plasma membrane (Butler et al. 2007). Similarly,
the C-terminal RSYQY sequence of the related SERCA regulator sarcolipin was
shown to mediate its retention in the ER (Gramolini et al. 2004). The present
results demonstrate an additional role for the PLB C-terminus in protein
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localization. It is noteworthy that small deletions are so poorly tolerated. Although
loss of only one C-terminal residue from the 22 amino acid TM domain of PLB
resulted in significant disruption of membrane localization, deletion of 4 or more
residues completely abolished localization. In accordance, deletion of 14 out of
22 TM residues in the heart failure mutant L39X completely abolished PLB
membrane localization, which was further supported by molecular dynamic
simulation studies (Abrol et al. 2014). This study highlights that despite the
presence of many other hydrophobic residues in the PLB TM domain, luminal
residues nearest the PLB C-terminus are critical for membrane anchoring.
PLB Mutations Alter the Structure and Oligomerization Affinity of PLB
Pentamer
In the SR membrane, PLB homopentamer exists in dynamic equilibrium
with the monomeric species that binds and inhibits SERCA. Maintenance of this
dynamic equilibrium between PLB monomer and pentamer is critical for SERCA
regulation, and thus, cardiac Ca2+ cycling and contractile function. We studied
the effect of mutations in PLB on monomer-pentamer equilibrium and
oligomerization affinity. Indeed, deletion and substitution mutations had distinct
effects on PLB oligomerization. While deletions decreased PLB-PLB binding
(Fig. 21B-i) without altering the pentamer structure, alanine substitutions
increased or decreased PLB pentamer FRETmax consistent with a structural
change (Fig. 21A-i) that alters the distance between FRET pairs. The structural
details of this putative change in pentamer quaternary conformation are not clear.
One possibility is that C-terminal substitutions alter PLB topology or perturb the
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structural equilibrium of PLB between T and R states (Karim et al. 2006,
Traaseth, Thomas, and Veglia 2006). It is noteworthy that the relatively
conservative substitution of Val49-to-Ala exerts an effect over such a long
distance, altering the position of fluorescent probes that are more than 40 Å away
(Fig. 5). Focusing on the heart failure mutants, truncating 14 residues of the 22
amino acid long TM domain in the L39X mutant significantly decreased FRETmax,
which can be attributed to loss of membrane anchoring, rather than a change in
pentamer structure. In addition, the affinity of PLB oligomerization for the L39X
mutant was too low to measure. Furthermore, substitution of Arg9 by Cys residue
in the R9C mutant altered the PLB pentamer conformation (Fig. 22A), and
increased PLB oligomerization affinity (Fig. 22B), shifting the equilibrium towards
the pentamer. Thus, specific mutations in PLB alter the equilibrium between PLB
monomer and pentamer. Our study highlights that mutations that cause a shift in
the PLB-monomer:pentamer equilibrium result in a change in structure and
oligomerization affinity of the PLB pentamer.
PLB Mutations Alter the Structure and Binding Affinity of SERCA-PLB
Regulatory Complex
The monomer-pentamer equilibrium plays a direct role in regulation of
SERCA and may affect the structure and binding affinity of SERCA-PLB
regulatory complex. We investigated the structural consequences of alanine
substitution and truncation mutations of PLB on SERCA-PLB regulatory complex.
Although determining the true quantitative affinity of monomeric PLB for SERCA
is complicated by oligomerization (Kelly et al. 2008) and differential protein
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localization, it is clear that substitution and deletion mutations exert opposite
effects on the apparent affinity of PLB for SERCA. V49A in particular shows a
significant increase in SERCA binding (Fig. 21A, ii), while deletions of residues
progressively decreases regulatory complex formation (Fig. 21B, ii). Both
deletions and substitutions of C-terminal residues caused large changes in the
regulatory complex structure (Fig. 21A and 21B, iii). Deleting only one Cterminal residue of PLB resulted in a 1.2-fold increase in FRETmax, which
corresponds to a distance change from 61.9 Å to 58.9 Å (Table 4). Truncating 4
C-terminal residues (V49X) increased FRETmax by more than 2-fold, which
corresponds to a 11.3 Å decrease in the distance between donor and acceptor
fluorophores (Table 4). Similarly, some Ala substitutions increased regulatory
complex intrinsic FRET, with V49A showing a 23% increase in FRETmax,
corresponding to a decrease in donor-acceptor distance of 3.3 Å. The magnitude
of these changes in FRET distance may be appreciated by considering that
functionally significant phosphomimetic mutations altered probe separation
distance by only 4 Å (Hou, Kelly, and Robia 2008). One possible explanation for
the observed structure change is that substitutions and deletions may cause
misregistration of PLB in the inhibitory cleft (Fig. 21A and 21B, iii). Translocation
of the TM domain could permit cytoplasmic domain repositioning, accounting for
the observed increase in FRET from a donor fluorophore on the SERCA Nterminus. This study reveals that Val49 appears to be particularly important in
setting the registration of the TM helix in the bilayer, affecting the disposition of
the adjacent TM domain and the more distant PLB cytoplasmic domain
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positioned on the other side of the bilayer, more than 40 Å away. As expected,
the heart failure mutant L39X exhibited a profound decrease in SERCA-PLB
FRETmax, and the affinity of SERCA-PLB regulatory complex for too low to
measure, indicating lack of SERCA regulation. We also evaluated the effect of
heart failure mutation, R9C on the regulatory complex structure. The R9C
mutation also altered the structure of SERCA-PLB regulatory complex (Fig.
22D), and exhibited decreased binding of PLB to SERCA (Fig. 22C). However,
this may be an indirect effect of decreased availability of monomeric PLB, rather
than a change in the intrinsic affinity of PLB for SERCA. In conclusion, both the
heart failure mutants of PLB including L39X and R9C exhibit decreased SERCA
binding and alter the structure of the SERCA-PLB regulatory complex.
PLB Mutations Alter the Function of SERCA-PLB Regulatory Complex
To establish disruption of PLB monomer-pentamer equilibrium as the
primary mechanism of cardiac Ca2+ mishandling, it is important to evaluate the
functional consequences of PLB mutations on SERCA activity. Given the
extreme sensitivity of PLB pentamer and regulatory complex structure to
mutations, we expected a robust alteration of PLB function and SERCA activity.
Alanine substitution has been a common mutagenesis strategy for understanding
how residues of PLB influence the functional regulation of SERCA (Kimura et al.
1996, Trieber, Afara, and Young 2009, Ceholski, Trieber, and Young 2012). This
method effectively removes the side chain of individual residues, thereby
providing information on their role in SERCA inhibition by PLB. In this study, we
investigated the functional consequences of the structural changes induced by
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alanine and truncation mutations. In measurements of SERCA ATPase activity in
the absence and presence of PLB, individual or multiple Ala substitutions
revealed a nexus for gain-of-function at Val49 of PLB (Abrol et al. 2014). The
gain-of-function was an unexpected outcome, and it contrasted sharply with the
deleterious effects of truncating these last few residues. Removal of just one
residue severely reduced PLB function, and removal of two or more residues
completely eliminated PLB function.
The most striking difference between the substitution and deletion mutants
is the disparate effects on PLB inhibitory function. The loss-of-function character
of the deletion mutants may be due in part to decreased membrane anchoring
(Fig. 21B, iv) and decreased SERCA binding (Fig. 21B, ii). Alternatively, the
putative misregistration of the PLB TM domain in the SERCA regulatory cleft may
result in a non-inhibitory interaction. We and others have previously provided
evidence that PLB and SERCA can interact in a non-inhibitory complex in the
presence of Ca2+ (Bidwell et al. 2011, Mueller et al. 2004, Li, Bigelow, and Squier
2004) or after PLB phosphorylation (Pallikkuth et al. 2013). This physiological
relief of inhibition also alters the affinity and structure of the PLB-SERCA
complex (Pallikkuth et al. 2013, Bidwell et al. 2011, Mueller et al. 2004, Li,
Bigelow, and Squier 2004). In contrast to deletion mutants or physiological
regulation, the structure change induced by L51A or V49A mutation is strongly
gain-of-function (Abrol et al. 2014). This observation is compatible with other
groups’ previous observations. Although V49A was initially reported to be a lossof-function mutation (Kimura et al. 1997, Minamisawa et al. 1999), subsequent
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studies have demonstrated that V49A is a gain-of-function mutation (Chen et al.
2006). A possible mechanism for this was revealed by X-ray crystallography,
which suggests that Val49 encounters steric hindrance from SERCA residue
Val89 (Akin et al. 2013). The present data support the hypothesis that replacing
PLB Val49 with a smaller residue can alleviate this hindrance, increasing the
affinity and potency of the inhibitory interaction (Haghighi et al. 2001, Chen et al.
2006, Akin et al. 2013). It is noteworthy that deleting Val49 does not produce the
same result, rather the affinity of the interaction is decreased, and even small
deletions of the C-terminal residues result in loss of inhibitory function.
Next, we evaluated the functional consequences of the R9C mutation of
PLB. Impaired regulation of SERCA by the R9C mutant results in blunted
sensitivity to local regulation (frequency potentiation) and humoral (-adrenergic)
stimulation. This fundamental lack of responsiveness to physiological stress
leads to pathological remodeling and heart failure caused by this mutant. The
failing heart suffers from prevailing oxidative stress (Choudhary and Dudley
2002), exacerbating the oxidative modification of R9C-PLB that initiated the
pathological pathway.
Chronic vs. Acute Effects of R9C Mutation of PLB
Previous studies of R9C-PLB showed that R9C-PLB is loss-of-function with
respect to SERCA inhibition (Schmitt et al. 2003, Schmitt et al. 2009, Ha et al.
2011, Ceholski, Trieber, and Young 2012). Such in vitro observations lead to the
expectation of enhanced SERCA activity and positive inotropy/lusitropy in vivo,
but this is not observed in transgenic models or in human patients. Specifically,

R9C-PLB transgenic mouse myocytes show slower Ca

2+
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handling kinetics

(Schmitt et al. 2003, Schmitt et al. 2009) compared to WT. We reasoned that
chronic exposure to R9C-PLB may elicit compensatory changes and the longterm disease evolution may not reveal the fundamental mechanistic defect. To
investigate the acute effect of R9C mutation of PLB, we introduced the mutated
protein to rabbit cardiac myocytes using an adenoviral vector delivery. On a
timescale of hours to days, the physiological effect of R9C-PLB is as predicted
from its loss-of-function character, with YFP-labeled R9C-PLB expressing
cardiac myocytes showing positive inotropy and lusitropy compared to YFP-WTPLB expressing myocytes (Fig. 9, Fig. 10). Thus, the impaired hemodynamics of
the mutant mouse may be long term consequences of secondary changes such
as decreased SERCA2a mRNA and protein expression, progressive intracellular
stress responses, cardiac remodeling, apoptotic signaling (Gramolini et al. 2008),
or other changes in gene expression or cell/organ structure that evolve over
weeks or months. We hypothesize that the fundamental pathological triggers of
this disease progression is blunted sensitivity to frequency potentiation and βadrenergic stimulation, such as is observed in the present acute physiological
measurements (Fig. 11). These two mechanisms are the main physiological
means of regulation of cardiac performance, and the lack of a functional
response to stress is expected to induce cardiac remodeling and related
decompensation processes. We conclude that transgenesis provides insight into
the progression of R9C-PLB disease (and heart failure more generally), while
acute delivery of mutant PLB provides insight into the fundamental Ca2+-handling
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defects that initiate this disease process.
Disordered Structure/Function Mechanisms of R9C-PLB
The molecular basis of R9C-PLB pathology is of great interest and several
possible mechanisms have been proposed. There is an emerging consensus that
R9C-PLB is loss-of-function with respect to inhibition of SERCA (Schmitt et al.
2003, Schmitt et al. 2009, Ha et al. 2011, Ceholski, Trieber, and Young 2012),
resulting in dysregulation of calcium cycling (Schmitt et al. 2003, Schmitt et al.
2009, Gramolini et al. 2008). There is also evidence for impaired phosphorylation
of R9C-PLB by PKA (Schmitt et al. 2003, Schmitt et al. 2009, Ha et al. 2011,
Ceholski et al. 2012). However, a cytoplasmic domain fragment of R9C-PLB was
phosphorylated by PKA with normal kinetics (Ha et al. 2011), suggesting that
there is not an intrinsic defect of PKA recognition of the R9C-PLB substrate.
Schmidt et al observed increased co-immunoprecipitation of R9C-PLB with PKA
(Schmitt et al. 2003), suggesting the mutated PLB physically traps and
inactivates the kinase, leading to impaired signaling and heart failure. While other
studies have failed to detect PKA cross-linking to R9C-PLB (Ha et al. 2011), it is
possible that PKA precipitation occurs secondary to other aggregation events, as
discussed below. Other possible mechanisms for R9C-PLB pathology include
decreased open probability of a putative PLB channel (Smeazzetto et al. 2013),
or disruption of hydrophobic balance of the PLB cytoplasmic domain leading to
loss of inhibitory function (Ceholski, Trieber, and Young 2012). In addition,
Gramolini et al reported that the impaired Ca2+ handling by the R9C mouse may
be a long term consequence of secondary changes such as decreased
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SERCA2a mRNA and protein expression, or activation of the endoplasmic
reticulum stress response, cytoskeletal remodeling, and apoptosis (Gramolini et
al. 2008). In addition to these diverse pathological mechanisms, we have
previously proposed that the introduced Cys residue may induce pathological
intersubunit cross-linking, stabilizing the R9C-PLB pentamer (Ha et al. 2011).
Evidence for this mechanism includes an increase in intrapentameric FRET for
the R9C-PLB mutant (Fig. 12A, Fig. 13), which is further enhanced by oxidative
stress (Fig. 13). In this regard, R9C-PLB crosslinking may mimic one of the
functional

effects

of

PLB

phosphorylation,

which

also

enhances

PLB

oligomerization (Simmerman and Jones 1998, Hou, Kelly, and Robia 2008,
Wegener and Jones 1984). The expected functional consequence of increased
PLB oligomerization is to reduce the availability of the inhibitory monomeric
species, decreasing SERCA inhibition. The acute physiological result of
decreased SERCA inhibition is apparent in the present experiments as a
positively inotropic and lusitropic effect (Fig. 9, Fig. 10). The data are consistent
with our previous observations in AAV-293 cells (Ha et al. 2011), and in the
present study we extend that analysis using pentamer-destabilizing mutations of
the transmembrane domain (Fujii et al. 1989) to more clearly isolate the effect of
R9C in stabilizing PLB pentamers. SSS-PLB has been presumed to be a fully
monomeric mutant based on SDS-PAGE mobility (Ceholski et al. 2012), but we
demonstrate here that SSS-PLB can still form low affinity pentamers (Fig. 12A)
Combining SSS and R9C mutations yielded an oxidation-sensitive mutant with a
basal level of oligomerization that was intermediate between WT-PLB and SSS-
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PLB (Fig. 13C). After oxidation with H2O2, SSS-R9C-PLB FRET increased
dramatically, achieving the same final value as R9C-PLB with a wild-type
transmembrane domain (Fig. 13C). The data suggest that the degree of
oligomerization is dominated by cross-linking of cytoplasmic Cys-9 residue of the
R9C-PLB pentamer.
R9C Acts as a Phosphomimetic Mutation of PLB
The transgenic expression of R9C-PLB in mouse hearts recapitulates many
aspects of human DCM (Schmitt et al. 2003, Schmitt et al. 2009), but the
fundamental molecular mechanism underlying the role of R9C-PLB in SERCA
regulation is still unclear. Proposed mechanisms include trapping of PKA
(Schmitt et al. 2003), disruption of PLB phosphorylation (Schmitt et al. 2003,
Schmitt et al. 2009, Ha et al. 2011, Ceholski et al. 2012), loss of PLB inhibitory
function (Schmitt et al. 2003, Schmitt et al. 2009, Ha et al. 2011, Ceholski et al.
2012, Ceholski, Trieber, and Young 2012). Notably, several studies have
suggested that the R9C mutation mimics PLB phosphorylation by partial
unfolding of the cytoplasmic helix resulting in decreased helical conformation
(Paterlini and Thomas 2005), or detachment of PLB cytoplasmic domain from
membrane surface (Yu and Lorigan 2013, 2014). Moreover, we have previously
proposed that R9C mutation induces oxidation-dependent cross-linking of
adjacent R9C-PLB protomers (Ha et al. 2011). This could also mimic the effect of
PLB phosphorylation in increasing oligomerization (Wegener and Jones 1984,
Simmerman and Jones 1998, Hou, Kelly, and Robia 2008), depleting the active
inhibitory monomeric species and relieving SERCA inhibition. Another aspect of
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R9C mutation that is reminiscent of PLB phosphorylation is the small decrease in
FRETmax for the R9C-PLB-SERCA regulatory complex (Fig. 12C, Table 3), a
difference that did not achieve statistical significance in a previous study (Ha et
al. 2011). The change in FRETmax suggests a conformational change that
increases the distance between the donor and acceptor fluorescent probes. This
is similar to the structure change that results from phosphomimetic mutations of
the PKA site (Ser-16) and CaMKII site (Thr-17) in the PLB cytoplasmic domain
(Hou, Kelly, and Robia 2008). The R9C-dependent structure transition and the
phosphorylation-dependent conformational change are similar in direction and
magnitude (+1.2 Å and +4 Å, respectively). A regulatory complex structure
change is the primary mechanism for relief of inhibition of SERCA by PLB
phosphorylation (Dong and Thomas 2014, Gustavsson et al. 2013). How R9C
mutation may imitate phosphorylation of PLB is not clear, but we speculate that
there may be a modification of the Cys at position 9 to a negatively charged
species that resembles phosphorylated residues of neighboring PKA/CaMKII
sites on PLB. Likely modifications include Cys deprotonation to a negatively
charged thiolate, or hyperoxidation to sulfenic, sulfinic, or sulfonic acid. By this
mechanism, the functional consequence of oxidative crosslinking of PLB
protomers in the pentamer would be reinforced by loss-of-function oxidative
modifications of remaining monomeric PLB. The data suggest that the
fundamental molecular mechanism underlying the R9C pathology is increased
sensitivity to oxidative challenge, which occurs periodically in the healthy heart
under conditions of physiological stress. Since these oxidative changes are
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poorly reversible (Ha et al. 2011), damage from transient oxidative episodes may
accumulate over time, leading to chronically impaired SERCA regulation,
disordered Ca2+ handling, and eventual heart failure.
Model for Structural and Functional Consequences of Alanine Substitution
and Truncation Mutations of PLB
The present observations are summarized in the schematic model of Fig.
21, with reversible equilibria indicated by black arrows and effects of mutations
highlighted with red arrows. Based on our findings, we propose that the alanine
substitution mutations of PLB C-terminus result in alteration of PLB pentamer
structure and decreased oligomerization affinity (Fig. 21A, i). In addition, alanine
substitution mutations also increased binding affinity of SERCA-PLB regulatory
complex (Fig. 21A, ii), and altered quaternary conformation of the SERCA-PLB
regulatory complex (Fig. 21A, iii). In comparison, C-terminal truncation mutants
of PLB decreased oligomerization affinity of PLB pentamer (Fig. 21B, i), and
decreased SERCA-PLB binding affinity (Fig. 21B, ii). C-terminal deletions also
altered the quaternary conformation of the SERCA-PLB regulatory complex (Fig.
21B, iii), and decreased membrane anchoring (Fig. 21B, iv). In conclusion, both
alanine and truncation mutants of PLB C-terminus resulted in alteration of
structure and function of SERCA-PLB regulatory complex. We conclude that the
C-terminal residues of PLB are important structural determinants, as mutations of
the C-terminal amino acids have significant effects on protein-protein interactions
and PLB quaternary structures. Despite the presence of many other hydrophobic
residues in the PLB TM domain, luminal residues nearest the PLB C-terminus
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are critical for membrane anchoring and structure determination of both the PLB
pentamer and the PLB-SERCA regulatory complex. It is noteworthy that both
deletions and Ala substitutions of PLB C-terminal residues increase SERCA-PLB
FRET, but have opposite effects on SERCA inhibition by PLB. Future detailed
structural studies of the PLB-SERCA regulatory complex may reveal how
substitutions and deletions at the C-terminal end of PLB can strongly alter the
disposition of the cytoplasmic domain on the other side of the membrane.
Model for Structural and Functional Consequences of PLB R9C Mutation
The structural and functional consequences of the R9C-PLB mutation are
summarized in Fig. 22. This scheme parallels our previous mechanistic model for
the relief of SERCA inhibition by phosphorylation (Hou, Kelly, and Robia 2008).
We propose that R9C mutation enhances transitions away from the inhibited
SERCA-PLB complex (Fig. 22, high FRET), leaving disinhibited SERCA (Fig. 22,
low FRET). R9C mutation altered the PLB pentamer conformation (Fig. 22A),
increased oligomerization affinity (Fig. 22B), and altered the structure of
regulatory complex (Fig. 22D). We also observed a decrease in binding of PLB
to SERCA (Fig. 22C). However, this may be an indirect effect of decreased
availability of monomeric PLB, rather than a change in the intrinsic affinity of PLB
for SERCA. We propose that the predominant mechanism underlying the
pathological effects of the R9C mutation is a phosphomimetic effect of PLB cys-9
oxidation. Focusing on the structural consequences of R9C mutation, we
observed that R9C mutation leads to increased PLB oligomerization, decreased
PLB-SERCA binding, and alteration of the structure of the regulatory complex.
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The functional consequences of the structural effects of R9C mutation were
decreased SERCA regulation, consistent with the observed increase in myocyte
contractility observed in the present acute experiments. The long-term inability of
R9C-PLB to regulate SERCA exerts a pathological effect by blunting sensitivity to
frequency potentiation and β-adrenergic stimulation, with consequent impaired
cardiac performance and eventual heart failure. Heart failure exacerbates
oxidative stress conditions, further enhancing R9C-PLB oligomerization, thus
reinforcing the pathological effects of the R9C mutation.
Summary
Many hereditary mutations of PLB have been reported to cause heart
failure in humans, underscoring the importance of PLB for calcium cycling and
contractility of the cardiac muscle. The work in this dissertation offers new
insights into the role of C-terminal residues of PLB as structural and functional
determinants of SERCA-PLB regulatory complex. We propose that the
transmembrane mutations alter the registration of PLB on SERCA. The Cterminal mutations may mimic translocation of PLB to a new binding site after
relief of inhibition by PLB phosphorylation or Ca2+ binding to SERCA. This study
confirms that in addition to the canonical binding site, there are multiple specific
binding sites for PLB on SERCA. We determine that the primary function of Cterminal residues of PLB is membrane anchoring, which is critical for PLB
oligomerization, and SERCA regulation. In addition, this study reports new
information about the mechanistic effect of two naturally-occurring PLB mutations
L39Stop and R9C, both of which have been shown to cause heart failure and
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premature death in humans. We report that both L39X and R9C mutants exhibit
alteration of PLB oligomerization and structure and function of the SERCA-PLB
regulatory complex. In particular, this study highlights that the oxidative changes
of the R9C-PLB protein mimic physiological phosphorylation, relieving inhibition
of SERCA. We propose that the increased sensitivity of R9C-PLB to oxidative
stress

causes

the

observed

hyperdynamic

phenotype

and

reduced

responsiveness to adrenergic signaling, leading to heart failure. We predict that
any other truncation or loss of function mutations in the transmembrane domain
of PLB, if found to occur naturally, would lead to cardiomyopathy due to alteration
of PLB-SERCA structure-function mechanisms. Since PLB gene is prone to
mutations, we propose to include PLB gene in genetic testing panels for patients
suffering from cardiac diseases.
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